A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia

CONCLUSION: For Chinese payers, zanubrutinib exhibited superior cost-effectiveness compared to ibrutinib. Zanubrutinib proved to be a more affordable option for US payers when considering the payment threshold.PMID:37999452 | DOI:10.1080/14737167.2023.2288683

Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 24, 2023 Category: Health Management Authors: Rongqi Li Chenxiang Wang Zhongjiang Ye Yizhang Chen Jingyao Xu Chuang Chen Jianhui Yang Jing Fu Tao Zhou Ziye Zhou Xiuhua Zhang Source Type: research